Navigation Links
Rempex Announces Series B Financing of Up to $67.5 Million
Date:11/9/2011

SAN DIEGO, Nov. 9, 2011 /PRNewswire/ -- Rempex Pharmaceuticals, Inc. today announced that it has completed the initial closing of a Series B financing.  New investors Frazier Healthcare Ventures and Vivo Ventures joined existing investors SV Life Sciences, OrbiMed Advisors and Adams Street Partners in committing to a total of $67.5 million for this round.  This financing, together with a previous Series A round, brings the total financing commitment for Rempex to $76 million since the company's founding in June 2011.

Rempex is focused on developing internally discovered new treatments for resistant gram-negative infections.  The company expects to file a New Drug Application (NDA) with the United States Food and Drug Administration (FDA) for its first product candidate in the second half of 2012 and an Investigational New Drug Application (IND) with the FDA for its second product candidate in the first quarter of 2012.

"We are very pleased to have been able to attract such a strong group of experienced healthcare investors," stated Daniel Burgess, President and Chief Executive Officer of Rempex.  "This financing gives us the resources to rapidly advance our development programs towards commercialization at a time when the need for new treatments for resistant gram-negative infections has become critical."

About Rempex Pharmaceuticals

Rempex Pharmaceuticals, Inc. is a biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company was founded to acquire all the assets, including financial and human resources, not associated with Aeroquin™ from Mpex Pharmaceuticals, Inc.  Aptalis Holdings Inc. acquired Mpex and its lead product candidate, Aeroquin™, earlier this year.  Company website: www.rempexpharma.com


'/>"/>
SOURCE Rempex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Amylin Pharmaceuticals Announces Date and Time Change to Previously Announced Presentation at the Credit Suisse 2011 Healthcare Conference
2. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... , ... October 13, 2017 , ... While it’s often ... a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She ... in darkness or restricted lighting. As such, it eliminates the need to turn on ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):